Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.82 |
| ▸ | VEGFA | P15692 | 8/20 | 0.82 |
| ▸ | FLT1 | P17948 | 8/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.82 |
| ▸ | TET3 | O43151 | 1/20 | 0.72 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.72 |
| ▸ | ASPH | Q12797 | 1/20 | 0.72 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.72 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.72 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.72 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.72 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921387 | 0.90 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30239178 | 0.90 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921950 | 0.90 | EGLN1 (0.69) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL20711145 | 0.90 | EGLN1 (0.66) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL26170368 | 0.89 | EGLN1 (0.77) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3485431 | 0.88 | EGLN1 (0.72) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL23501756 | 0.87 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933469 | 0.87 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL15164149 | 0.85 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3484507 | 0.85 | EGLN1 (0.60) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47437-E1 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | claimed |
| US-9598370-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-8598210-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | claimed |
| US-20130203816-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | AKEBIA THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3007695-B1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11857543-B2 | Compositions and methods for treating anemia | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857543-B2 | Compositions and methods for treating anemia | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20160339005-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AKEBIA THERAPEUTICS, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160339005-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AKEBIA THERAPEUTICS, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016161094-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160143891-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160143891-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015112831-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AKEBIA THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2014200773-A2 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS , INC. (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143891-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | HIF1AN, EGLN3, EGLN2 | EGLN1 5/4885VEGFA 395/4885FLT1 318/4885 |
| US-20160339005-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP4 | EGLN1 2391/4885VEGFA 1/4885FLT1 6/4885 |
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20130203816-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | DIMT1, HIF1A, HIF1AN | EGLN1 912/4885VEGFA 269/4885FLT1 2371/4885 |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | EGLN1 1247/4885VEGFA 747/4885FLT1 2745/4885 |
| US-11857543-B2 | Compositions and methods for treating anemia | HIF1AN, EGLN3, EGLN2 | EGLN1 5/4885VEGFA 395/4885FLT1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.